Gynecologic Oncology Group Notifies CTI That Continuation Of GOG-212 Pivotal Trial Of OPAXIO Maintenance Therapy In Ovarian Cancer Is A Priority

Posted by Jeff Daas on Mar 5th, 2010 | no comments

Cell Therapeutics, Inc. (“CTI”) (Nasdaq and MTA: CTIC) announced that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI’s OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue…
Read Full Article